Rayno Biopharmaceuticals Portfolio Performance 9/30/17 YTD
Rayno Biopharmaceuticals Portfolio: Performance 9/30/17 YTD Objective: Develop a medium term biotech portfolio that assumes a bull market for 2017 with positions in two core ETFs, large cap dividend plays and speculative picks in breakthrough technologies: CAR-T and pharmacogenomics. Most...
Rayno BioBeat #5: XBI Breaks Through on a Strong Week for Biotech
Biotech Stocks Break Through to 2017 Highs in a Broad Rally NASDAQ up 066%, IBB up 0.92%, XBI up 0.8% The XBI is up 3.17% this week, 46% YTD, compared to only 1.1% WTD for the IBB. The breakthrough gains for the XBI can be attributed to strong performance of top ten holdings that are primarily...
Rayno Diagnostics and Tools Revisited: Sector Outperformance That Tracks Biotech
Life Science Tools and Services Stocks Have Outperformed Biopharmaceuticals With Less Volatility Large Caps Are Winners in 2017 We have not covered the Life Science Tools and Diagnostics sector since early 2016 when life science stocks abruptly sold off. We have focused on biotech ETFs and...
Biotech Bull Market Update: Five Year Performance for Life Science Funds and ETFs
Biotech Bull Market: XBI is leader for 2017 and Over Five Years The FBT First Trust Arca Outperformed Up 157% Over Five Years In 2016 the Sector Underperformed After the 2015 Downdraft Here is our July 2013 review of several top Life Science Funds and ETFs . Over five years below we have...
Biotech Momentum Eases: September is a Bit Sluggish…Update after FED Meeting-9/20
Markets Stable After Major FED Meeting: On Course for Gradual QT(Quantitative Tightening) FED to shrink assets by year end, 2 yr TSY up to 1.43% yield. Biotech stocks up slightly near September Top IBB $332.75, XBI $85.17. Large caps green: growth and value perceived: ABBV and REGN are leaders...